End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

被引：44

作者：

Jacobson, Caron A. ^{[1
]}

Locke, Frederick L. ^{[2
]}

Miklos, David B. ^{[3
]}

Herrera, Alex F. ^{[4
]}

Westin, Jason R. ^{[5
]}

Lee, Jennifer ^{[6
]}

Rossi, John M. ^{[6
]}

Zheng, Lianqing ^{[6
]}

Avanzi, Mauro P. ^{[6
]}

Roberts, Zachary J. ^{[6
]}

Sun, Jennifer ^{[6
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[3] Stanford Univ, Dept Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA

[4] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA

[5] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Kite, Santa Monica, CA USA

来源：

关键词：

D O I：

10.1182/blood-2018-99-111523

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4192

引用

页数：3